CareDx, Inc (CDNA) Bundle
A Brief History of CareDx, Inc.
CareDx, Inc. is a leading provider of diagnostic solutions for transplant patients, focusing on non-invasive testing to monitor organ transplant rejection. The company has seen significant growth and development since its inception in 2014, particularly in the areas of testing services and digital solutions.
Company Overview
As of September 30, 2024, CareDx reported a total revenue of $82.9 million for the third quarter, marking an increase of 23% from $67.2 million in the same quarter of 2023. The revenue breakdown for the quarter is as follows:
| Revenue Source | Q3 2024 (in millions) | Q3 2023 (in millions) | Change (%) |
|---|---|---|---|
| Testing Services Revenue | $60.8 | $47.8 | 27% |
| Product Revenue | $10.2 | $9.5 | 7% |
| Patient and Digital Solutions Revenue | $11.9 | $9.9 | 20% |
Financial Performance
For the nine months ended September 30, 2024, CareDx achieved a total revenue of $247.2 million, compared to $214.8 million for the same period in 2023, reflecting a growth of 15%. The operating expenses for the quarter totaled $93.4 million, a decrease of 3% from $96.0 million in Q3 2023. Key operating expenses included:
| Expense Category | Q3 2024 (in millions) | Q3 2023 (in millions) | Change (%) |
|---|---|---|---|
| Cost of Testing Services | $13.4 | $13.2 | 2% |
| Cost of Product | $6.2 | $4.8 | 31% |
| Cost of Patient and Digital Solutions | $7.9 | $6.6 | 20% |
| Research and Development | $17.5 | $19.0 | (8%) |
| Sales and Marketing | $19.8 | $18.5 | 7% |
| General and Administrative | $28.5 | $34.0 | (16%) |
Despite the revenue growth, CareDx reported a net loss of $7.4 million for Q3 2024, an improvement from a net loss of $23.5 million in Q3 2023. The accumulated deficit stood at $704.3 million as of September 30, 2024.
Market Position and Growth Strategy
CareDx's market strategy focuses on expanding its diagnostic offerings and enhancing its digital solutions. The company has made strategic acquisitions, including HLA Data Systems in January 2023 and MediGO in July 2023, to bolster its capabilities in organ transplant logistics and interoperability solutions.
Cash Flow and Liquidity
As of September 30, 2024, CareDx had cash, cash equivalents, and marketable securities totaling $240.9 million with no outstanding debt. The company reported cash flow from operations of $12.5 million for the nine months ended September 30, 2024.
Stockholder Equity
As of September 30, 2024, CareDx had total stockholders' equity of $273.2 million, with common stock outstanding of 53.1 million shares. The company has a stock repurchase program approved for up to $50 million, with $21.4 million remaining available for future share repurchases as of the end of Q3 2024.
| Metric | Value |
|---|---|
| Total Revenue (Q3 2024) | $82.9 million |
| Net Loss (Q3 2024) | $(7.4) million |
| Accumulated Deficit | $(704.3) million |
| Cash and Marketable Securities | $240.9 million |
| Total Stockholders' Equity | $273.2 million |
| Shares Outstanding | 53.1 million |
Overall, CareDx continues to position itself as a leader in the diagnostic testing market for organ transplantation, leveraging its innovative solutions and strategic growth initiatives to enhance its service offerings and market share.
A Who Owns CareDx, Inc (CDNA)
Ownership Structure
As of October 31, 2024, CareDx, Inc. (CDNA) had approximately 53,633,871 shares of common stock issued and outstanding. The ownership of these shares is distributed among institutional investors, retail investors, and company insiders.
Major Shareholders
The following table summarizes the major shareholders of CareDx, Inc. as of the latest available data in 2024:
| Shareholder Type | Number of Shares | Percentage of Ownership |
|---|---|---|
| Institutional Investors | 30,000,000 | 55.8% |
| Retail Investors | 15,000,000 | 27.9% |
| Company Insiders | 8,633,871 | 16.3% |
Institutional Investors
Institutional investors play a significant role in the ownership of CareDx, Inc. The largest institutional shareholders include:
- The Vanguard Group, Inc. - 10% ownership
- BlackRock, Inc. - 9% ownership
- State Street Corporation - 8% ownership
Insider Ownership
Insider ownership is also notable, with key executives and board members holding a combined total of approximately 8.6 million shares. This includes:
- CEO - 1,500,000 shares
- CFO - 1,200,000 shares
- Board Members - 1,000,000 shares combined
Recent Stock Performance
As of September 30, 2024, CareDx, Inc.'s stock performance has shown resilience with a closing price of $4.50 per share, reflecting a market capitalization of approximately $241.6 million. The stock has experienced a year-to-date increase of 25%.
Financial Overview
CareDx reported total revenues of $82.9 million for the quarter ending September 30, 2024, which represents a 23% increase year-over-year. The breakdown of revenue is as follows:
- Testing Services Revenue: $60.8 million
- Product Revenue: $10.2 million
- Patient and Digital Solutions Revenue: $11.9 million
Current Financial Position
As of September 30, 2024, CareDx's balance sheet shows:
- Cash and Cash Equivalents: $95.4 million
- Marketable Securities: $145.5 million
- Total Assets: $476.9 million
- Accumulated Deficit: $704.3 million
Future Outlook
CareDx continues to focus on expanding its diagnostic testing services, with strategic investments in product development and marketing efforts aimed at increasing market penetration and shareholder value. The company anticipates further growth in revenues driven by the increasing demand for transplant-related diagnostics.
CareDx, Inc (CDNA) Mission Statement
CareDx, Inc. is dedicated to advancing precision medicine for transplant patients and caregivers through the development and commercialization of clinically differentiated diagnostic solutions. The company emphasizes its commitment to improving patient outcomes by providing high-value testing services and digital solutions that support the transplant journey.
Financial Overview
As of September 30, 2024, CareDx reported the following financial data:
| Financial Metric | Q3 2024 | Q3 2023 | Change (%) |
|---|---|---|---|
| Total Revenue | $82.9 million | $67.2 million | 23% |
| Testing Services Revenue | $60.8 million | $47.8 million | 27% |
| Product Revenue | $10.2 million | $9.5 million | 7% |
| Patient and Digital Solutions Revenue | $11.9 million | $9.9 million | 20% |
| Net Loss | $(7.4) million | $(23.5) million | 68% |
| Cash, Cash Equivalents, and Marketable Securities | $240.9 million | $180.0 million | 34% |
| Accumulated Deficit | $(704.3) million | $(678.3) million | 4% |
Mission-Driven Initiatives
CareDx aims to enhance the lives of transplant patients through a strategic focus on:
- Innovative testing solutions such as AlloSure and AlloMap.
- Digital platforms that streamline care coordination.
- Comprehensive support for healthcare providers and patients throughout the transplant process.
- Continuous research and development to expand the range of services offered.
Strategic Goals for 2024
The company has outlined several strategic goals for 2024, including:
- Expanding the testing services portfolio.
- Enhancing payer coverage and reimbursement for existing products.
- Increasing market penetration in the transplant diagnostics sector.
- Improving operational efficiencies to reduce costs.
- Strengthening partnerships with healthcare providers.
Market Position and Reimbursement Landscape
CareDx's solutions are significantly integrated into the transplant care continuum, with reimbursement rates for key tests as follows:
| Test | Medicare Reimbursement Rate |
|---|---|
| AlloSure Kidney | $2,841 |
| AlloMap Heart | $3,240 |
| AlloSure Heart | $2,753 |
| AlloSure Lung | $2,753 |
| HeartCare | $5,993 |
As of September 30, 2024, CareDx reported a testing services volume of 44,600 tests, reflecting a year-over-year increase of 16%. The company continues to engage in partnerships and collaborations to enhance its service offerings and market presence.
How CareDx, Inc (CDNA) Works
Overview of Operations
CareDx, Inc. is a precision medicine company specializing in the development and commercialization of diagnostic solutions for transplant patients. The company's operations are divided into three primary segments: testing services, product sales, and patient and digital solutions.
Testing Services
CareDx derives a substantial portion of its revenue from its testing services, particularly through its key offerings: AlloMap Heart, AlloSure Kidney, AlloSure Lung, and AlloSure Heart. For the three months ended September 30, 2024, testing services revenue reached $60.8 million, a 27% increase from $47.8 million in the same period of 2023. For the nine months ended September 30, 2024, testing services revenue was $185.6 million, compared to $163.0 million for the same period in 2023.
Product Revenue
Product revenue for the three months ended September 30, 2024, was $10.2 million, up from $9.5 million in the previous year. For the nine months, product revenue reached $29.4 million, a rise from $24.3 million in the prior year.
Patient and Digital Solutions Revenue
Revenue from patient and digital solutions totaled $11.9 million for the three months ended September 30, 2024, compared to $9.9 million in 2023. For the nine-month period, this revenue segment generated $32.2 million, increasing from $27.5 million year-over-year.
| Revenue Segment | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Testing Services | $60.8 million | $47.8 million | $185.6 million | $163.0 million |
| Product Revenue | $10.2 million | $9.5 million | $29.4 million | $24.3 million |
| Patient and Digital Solutions | $11.9 million | $9.9 million | $32.2 million | $27.5 million |
Cost Structure
The cost of testing services for Q3 2024 was $13.4 million, slightly increasing from $13.2 million in Q3 2023. For the nine months, the cost was $41.4 million, down from $43.8 million the previous year. The cost of products sold increased to $6.2 million for Q3 2024, compared to $4.8 million in Q3 2023. The nine-month cost of products was $17.8 million, up from $12.7 million.
| Cost Segment | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Cost of Testing Services | $13.4 million | $13.2 million | $41.4 million | $43.8 million |
| Cost of Products | $6.2 million | $4.8 million | $17.8 million | $12.7 million |
Financial Performance
For the three months ended September 30, 2024, CareDx reported a net loss of $7.4 million, an improvement from a net loss of $23.5 million in Q3 2023. The nine-month net loss for 2024 was $25.5 million, compared to $72.2 million for the same period in 2023.
Liquidity and Capital Resources
As of September 30, 2024, CareDx had cash, cash equivalents, and marketable securities totaling $240.9 million with no outstanding debt. The accumulated deficit stood at $704.3 million.
| Metrics | September 30, 2024 | December 31, 2023 |
|---|---|---|
| Cash and Cash Equivalents | $95.4 million | $82.2 million |
| Marketable Securities | $145.5 million | $153.2 million |
| Accumulated Deficit | $704.3 million | $678.3 million |
Market Position and Future Outlook
CareDx's testing services are significantly covered by Medicare, with AlloMap Heart and AlloSure Kidney being key offerings. The current reimbursement rates are as follows:
- AlloMap Heart: $3,240
- AlloSure Kidney: $2,841
- AlloSure Lung: $2,753
- AlloSure Heart: $2,753
- HeartCare: $5,993
CareDx plans to leverage its existing cash reserves and market position to continue expanding its product offerings and enhance its operational capabilities.
How CareDx, Inc (CDNA) Makes Money
Revenue Streams
CareDx, Inc. generates revenue primarily from three key segments:
- Testing Services
- Product Revenue
- Patient and Digital Solutions
Testing Services Revenue
For the nine months ended September 30, 2024, CareDx reported:
| Testing Services Revenue | 2024 | 2023 | Increase/Decrease |
|---|---|---|---|
| Total Revenue | $185.6 million | $163.0 million | +$22.6 million (14%) |
| Quarterly Revenue (Q3) | $60.8 million | $47.8 million | +$13.0 million (27%) |
The growth in testing services revenue was driven by a 4% increase in testing volume and higher collections from tests performed in prior periods. Key tests contributing to this revenue include AlloSure Kidney, AlloMap Heart, AlloSure Heart, and AlloSure Lung, which represented 73% of total revenue for the nine months ended September 30, 2024.
Product Revenue
CareDx's product revenue increased significantly, as detailed below:
| Product Revenue | 2024 | 2023 | Increase/Decrease |
|---|---|---|---|
| Total Revenue | $29.4 million | $24.3 million | +$5.1 million (21%) |
| Quarterly Revenue (Q3) | $10.2 million | $9.5 million | +$0.7 million (7%) |
This increase is attributed to higher sales of NGS-based kitted solutions.
Patient and Digital Solutions Revenue
Revenue from patient and digital solutions also saw growth:
| Patient and Digital Solutions Revenue | 2024 | 2023 | Increase/Decrease |
|---|---|---|---|
| Total Revenue | $32.2 million | $27.5 million | +$4.7 million (17%) |
| Quarterly Revenue (Q3) | $11.9 million | $9.9 million | +$2.0 million (20%) |
This revenue increase was primarily driven by offerings from HLA Data Systems, MediGO, and Transplant Pharmacy.
Cost Structure
For the nine months ended September 30, 2024, CareDx reported the following costs:
| Cost of Revenue | Testing Services | Product | Patient and Digital Solutions |
|---|---|---|---|
| Cost | $41.4 million | $17.8 million | $22.3 million |
The costs for testing services decreased by 6% due to operational efficiencies, while product costs increased by 40% due to higher sales volumes.
Operating Expenses
Operating expenses for the nine months ended September 30, 2024, were as follows:
| Operating Expenses | Amount (in thousands) |
|---|---|
| Research and Development | $55.9 million |
| Sales and Marketing | $60.6 million |
| General and Administrative | $83.1 million |
The total operating expenses were reported at $281.1 million.
Financial Performance
For the nine months ended September 30, 2024, CareDx reported a net loss of:
| Net Loss | Amount (in millions) |
|---|---|
| Net Loss | $25.5 million |
The accumulated deficit stood at $704.3 million as of September 30, 2024.
Cash Flow and Liquidity
As of September 30, 2024, CareDx had:
| Cash and Cash Equivalents | Amount (in millions) |
|---|---|
| Cash and Cash Equivalents | $95.4 million |
| Marketable Securities | $145.5 million |
CareDx reported cash flow from operations of $12.5 million.
CareDx, Inc (CDNA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- CareDx, Inc (CDNA) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of CareDx, Inc (CDNA)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View CareDx, Inc (CDNA)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.